BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.


 Key Statistics


Email:
Ownership: Public

Web Site: Emergent BioSolutions
Employees:
Symbol: EBS
 









 Company News
Emergent BioSolutions (EBS) To Webcast Presentation At 25th Annual Oppenheimer Healthcare Conference 11/24/2014 1:48:45 PM
Drugmakers Like Johnson & Johnson (JNJ), Emergent BioSolutions (EBS), And Mapp Biopharmaceutical Stand To Gain Ebola Contracts Worth $2 Billion 11/11/2014 6:48:25 AM
Emergent BioSolutions (EBS) Seeks Expanded Biothrax Label; Submits FDA Application For Post-Exposure Prophylaxis 11/10/2014 8:19:05 AM
Emergent BioSolutions (EBS) Reports Third Quarter And Nine Month 2014 Financial Results 11/7/2014 8:26:38 AM
Emergent BioSolutions (EBS) To Webcast Presentation At Credit Suisse 2014 Healthcare Conference 10/20/2014 7:19:51 AM
Prophylix Pharma Signs Manufacturing Agreement With Emergent BioSolutions (EBS) 10/14/2014 2:26:16 PM
Emergent BioSolutions (EBS) To Release Third Quarter 2014 Financial Results And Conduct A Conference Call On November 6, 2014 10/9/2014 10:41:40 AM
Emergent BioSolutions (EBS) Initiates Final Pivotal Study To Support Licensure Of BioThrax At Large Scale 9/23/2014 11:30:03 AM
Emergent BioSolutions (EBS) Awarded $29 Million Contract To Develop A Dry Formulation Of Nuthrax 9/9/2014 11:02:37 AM
Emergent BioSolutions (EBS) Awarded Contract To Develop A Dry Formulation Of Nuthrax, A Next Generation Anthrax Vaccine 9/8/2014 12:35:37 PM
12345678910...